{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for adenosine in Standardized Name (approximate match)
Status:
Investigational
Source:
INN:marpinersen [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT03373786: Phase 1 Interventional Completed Alport Syndrome
(2017)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT04516291: Phase 2 Interventional Completed Dyslipidemias
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:tivanisiran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02610296: Phase 3 Interventional Completed Delayed Graft Function
(2016)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:pozetaldogene ormesparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ristoglogene autogetemcel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rivunatpagene miziparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04140539: Phase 2/Phase 3 Interventional Withdrawn Severe Combined Immunodeficiency Due to ADA Deficiency
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE